{"organizations": [], "uuid": "4a9babcc0d3e5043f6bb6b7975b48817e7864411", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-zealand-pharma-announces-progress/brief-zealand-pharma-announces-progress-to-phase-3-with-dasiglucagon-for-the-treatment-of-congenital-hyperinsulinism-idUSASM000IB6", "country": "US", "domain_rank": 408, "title": "BRIEF-Zealand Pharma Announces Progress To Phase 3 With Dasiglucagon For The Treatment Of Congenital Hyperinsulinism", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-20T00:36:00.000+02:00", "replies_count": 0, "uuid": "4a9babcc0d3e5043f6bb6b7975b48817e7864411"}, "author": "", "url": "https://www.reuters.com/article/brief-zealand-pharma-announces-progress/brief-zealand-pharma-announces-progress-to-phase-3-with-dasiglucagon-for-the-treatment-of-congenital-hyperinsulinism-idUSASM000IB6", "ord_in_thread": 0, "title": "BRIEF-Zealand Pharma Announces Progress To Phase 3 With Dasiglucagon For The Treatment Of Congenital Hyperinsulinism", "locations": [], "entities": {"persons": [], "locations": [{"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "brief-zealand pharma", "sentiment": "negative"}, {"name": "treatment of congenital hyperinsulinism reuters", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 19 (Reuters) - Zealand Pharma A/S:\n* ZEALAND PHARMA ANNOUNCES PROGRESS TO PHASE 3 WITH DASIGLUCAGON FOR THE TREATMENT OF CONGENITAL HYPERINSULINISM IN FIRST HALF 2018\n* ZEALAND PHARMA - U.S. FDA APPROVED ZEALAND‘S INVESTIGATIONAL NEW DRUG APPLICATION FOR INITIATION OF TWO PHASE 3 CLINICAL TRIALS OF DASIGLUCAGON IN CHI​ Source text for Eikon: Further company coverage:\n ", "external_links": [], "published": "2018-01-20T00:36:00.000+02:00", "crawled": "2018-01-20T00:54:43.004+02:00", "highlightTitle": ""}